Clinical Trial

A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-17; most recent amendment 2026-05-07.
Trial Details
NCT Number NCT07219030
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 40 participants
Start Date 2025-10-08
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-12